コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 conversion of UDP-GlcNAc into UDP-N-acetyl-D-mannosamine.
3 which in Nm serogroup A consists of N-acetyl-mannosamine-1-phosphate units linked together by phospho
5 (Glc6P), and a nonnatural activating sugar, mannosamine 6-phosphate (MaN6P), reveal a binding mode s
6 charide standard plots for respective sugars mannosamine-6-phosphate, sialic acid, galactose- and glu
12 ls were grown in the presence of synthetic d-mannosamine analogues that can modify the conformation o
14 onversion of a panel of azide-functionalized mannosamine and glucosamine derivatives into cell-surfac
16 by metabolic conversion of synthetic N-acyl mannosamines and are typically incorporated into cell-su
17 cells were incubated with different N-acyl-d-mannosamines, and modified forms of GM3 expressed on tum
18 ve activities toward d-allose and N-acetyl-d-mannosamine are largely unaffected by the glucokinase-en
20 by exogenously added N-acetylmannosamine or mannosamine but not by the same concentrations of N-acet
23 mine 2-epimerase (wecB) and a UDP-N-acetyl-d-mannosamine dehydrogenase (wecC) were identified in the
24 nthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of t
25 ere was a significant azido-labeled N-acetyl-mannosamine-dependent increase in tumor-to-tissue contra
27 ailable amino sugars, including glucosamine, mannosamine, galactosamine, and muramic acid, as laborat
28 a, or uridine but not by control metabolites mannosamine, galactose, mannose, succinate, or pyruvate.
29 h any other sugar, including: galactosamine, mannosamine, Glc, GlcNAc, GalNAc, mannose, 2-deoxyglucos
31 Starting from the commercially available D-mannosamine hydrochloride (5), gram quantities of both 1
32 two readily available starting materials, D-mannosamine hydrochloride and the microbial oxidation pr
33 ne sulfate, galactosamine hydrochloride, and mannosamine hydrochloride-were examined for the linearit
38 ody fluids showed an elevation in N-acetyl-D-mannosamine levels, and patient-derived fibroblasts had
39 gulatory functions, was examined utilizing D-mannosamine (ManN) as a tool to identify mannosyltransfe
40 eport the identification of the hexosamine D-mannosamine (ManN) as an EC mitogen and survival factor
43 thway in mammalian cells utilizes N-acetyl-D-mannosamine (ManNAc) as a natural metabolic precursor an
44 we fed the sialic acid precursor N-acetyl-D-mannosamine (ManNAc) to NPHS2-Angptl4 transgenic rats it
45 of glucose (Glc), galactose (Gal), N-acetyl mannosamine (ManNAc), and N-acetylglucosamine (GlcNAc).
48 riers were then conjugated with N-butanoyl-d-mannosamine (ManNBut) with a goal to achieve modulation
49 reference for the same geometry that put the mannosamine moiety of one substituent close to the thiou
51 lth like the structural analogues N-acetyl-D-mannosamine (NADM) and N-acetyl-D-glucosamine (NADG).
52 he anomeric n-pentenyl glycosides of N-Cbz 2-mannosamine oxazolidinones were converted separately to
54 on with the sialic acid precursor N-acetyl-D-mannosamine restored IgG sialylation and preserved insul
55 italicus TagA enzyme bound to UDP-N-acetyl-d-mannosamine, revealing the molecular basis of substrate
56 onjugated with triacetylated N-azidoacetyl-d-mannosamine (RR-S-Ac3 ManNAz) was developed to enable tu
57 atalysis by encapsulating the UDP-N-acetyl-d-mannosamine substrate, presenting three highly conserved
58 s (CTLs) were incubated with N-azidoacetyl-D-mannosamine-tetraacylated (Ac(4)ManNAz) for incorporatin
59 ells an unnatural monosaccharide, a modified mannosamine that replaced the acetyl group with a levuli
60 ugate vaccine with systemic N-phenylacetyl-d-mannosamine treatment is a promising immunotherapy for f
63 utanoyl, and N-phenylacetyl derivatives of d-mannosamine were synthesized, and their efficiency as bi
64 saccharides, glucosamine, galactosamine, and mannosamine, were derivatized with [Co(DAP)2Cl2]Cl, and
65 with K1 >3000 m(-1) for axially substituted mannosamine, whereas a positively charged version binds